Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells in Spinal Cord Injury
NCT04288934Phase 1Completed
- Sponsor
- University of Jordan
- Start
- Aug 2017
- Primary completion
- Apr 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone marrow derived mesenchymal stromal cells and wharton's jelly mesenchymal stromal cells in spinal cord injury (SCI) (2 arms), sponsored by University of Jordan. Primary endpoints: ASIA Impairment Scale at 12 months, Spinal Cord Independence Measure version III at 12 months and 3 more. Started Aug 2017; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cellswharton's jelly mesenchymal stromal cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04288934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288934.